THE FGFR3 MUTATION IS RELATED TO FAVORABLE PT1 BLADDER CANCER

被引：0
|
作者：
Van Rhijn, B. W. G. [1 ]
Bapat, B. [2 ]
Van Der Kwast, T. H. [3 ]
Liu, L. [2 ]
Fleshner, N. E. [1 ]
Van Der Aa, M. N. M. [4 ]
Vajpeyi, R. [1 ]
Bangma, C. H. [4 ]
Zwarthoff, E. C. [5 ]
Jewett, M. A. S. [1 ]
Zlotta, A. R. [1 ]
机构：
[1] Univ Toronto, Univ Hlth Network, Dept Surg Oncol Urol, Toronto, ON, Canada
[2] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Dept Lab Med & Pathobiol, Toronto, ON M5G 1X5, Canada
[3] Univ Toronto, Univ Hlth Network, Dept Surg Pathol, Toronto, ON, Canada
[4] Erasmus MC, Dept Urol, Rotterdam, Netherlands
[5] Erasmus MC, Dept Pathol, Rotterdam, Netherlands
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2009年 / 8卷 / 04期
关键词：
D O I：
10.1016/S1569-9056(09)60313-4
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：197 / 197
页数：1
相关论文
共 50 条
  • [21] Usefulness of droplet digital PCR and Sanger sequencing for detection of FGFR3 mutation in bladder cancer
    Borkowska, Edyta Marta
    Traczyk-Borszynska, Magdalena
    Kutwin, Piotr
    Pietrusinski, Michal
    Jablonowski, Zbigniew
    Borowiec, Maciej
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (12) : 907 - 915
  • [22] FGFR3 mutation analysis in urine samples can be used as marker of bladder cancer detection
    Alameda, F.
    Segales, L.
    Lorenzo, M.
    Juanpere, N.
    Soler, I.
    Lloveras, B.
    Lloreta, J.
    Hernandez-Llodra, S.
    VIRCHOWS ARCHIV, 2017, 471 : S270 - S270
  • [23] No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer
    Otto, Wolfgang
    Denzinger, Stefan
    Bertz, Simone
    Gaumann, Andreas
    Wild, Peter J.
    Hartmann, Arndt
    Stoehr, Robert
    INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (09) : 2205 - 2208
  • [24] FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer
    Neuzillet, Yann
    van Rhijn, Bas W. G.
    Prigoda, Nadia L.
    Bapat, Bharati
    Liu, Liyang
    Bostrom, Peter J.
    Fleshner, Neil E.
    Gallie, Brenda L.
    Zlotta, Alexandre R.
    Jewett, Michael A. S.
    van der Kwast, Theo H.
    VIRCHOWS ARCHIV, 2014, 465 (02) : 207 - 213
  • [25] Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
    Andrew J. Weickhardt
    David K. Lau
    Margeaux Hodgson-Garms
    Austen Lavis
    Laura J. Jenkins
    Natalia Vukelic
    Paul Ioannidis
    Ian Y. Luk
    John M. Mariadason
    BMC Cancer, 22
  • [26] FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer
    Yann Neuzillet
    Bas W. G. van Rhijn
    Nadia L. Prigoda
    Bharati Bapat
    Liyang Liu
    Peter J. Bostrom
    Neil E. Fleshner
    Brenda L. Gallie
    Alexandre R. Zlotta
    Michael A. S. Jewett
    Theo H. van der Kwast
    Virchows Archiv, 2014, 465 : 207 - 213
  • [27] Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
    Weickhardt, Andrew J.
    Lau, David K.
    Hodgson-Garms, Margeaux
    Lavis, Austen
    Jenkins, Laura J.
    Vukelic, Natalia
    Ioannidis, Paul
    Luk, Ian Y.
    Mariadason, John M.
    BMC CANCER, 2022, 22 (01)
  • [28] Distinct tumor microenvironment in FGFR3 Alternations for Bladder Cancer
    Komura, Kazumasa
    Nishimura, Kazuki
    Tsujino, Takuya
    Inamoto, Teruo
    Taniguchi, Kohei
    Hayashi, Takuo
    Hirose, Yoshinobu
    Shiraishi, Yuichi
    Yoshimi, Akihide
    Azuma, Haruhito
    CANCER SCIENCE, 2024, 115 : 250 - 250
  • [29] FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
    Kacew, Alec
    Sweis, Randy F.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [30] Sex bias in FGFR3 somatic mutations in bladder cancer
    Xiangyu Meng
    Qiaoli Wang
    Oncology and Translational Medicine, 2024, 10 (05) : 252 - 256
12345